WO1996037610A3 - Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders - Google Patents
Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders Download PDFInfo
- Publication number
- WO1996037610A3 WO1996037610A3 PCT/IB1996/000696 IB9600696W WO9637610A3 WO 1996037610 A3 WO1996037610 A3 WO 1996037610A3 IB 9600696 W IB9600696 W IB 9600696W WO 9637610 A3 WO9637610 A3 WO 9637610A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cck
- signal transduction
- methods
- diagnosis
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to CCK-4 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a CCK-4 receptor tyrosine kinase and a receptor for the kinase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62386/96A AU6238696A (en) | 1995-05-25 | 1996-05-24 | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45263095A | 1995-05-25 | 1995-05-25 | |
US08/452,630 | 1995-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996037610A2 WO1996037610A2 (en) | 1996-11-28 |
WO1996037610A3 true WO1996037610A3 (en) | 1997-01-16 |
Family
ID=23797255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/000696 WO1996037610A2 (en) | 1995-05-25 | 1996-05-24 | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6238696A (en) |
WO (1) | WO1996037610A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
WO2005063987A1 (en) * | 2003-12-19 | 2005-07-14 | Aveo Pharmaceuticals, Inc. | Gp153: methods and compositions for treating cancer |
CN101360761B (en) | 2005-12-08 | 2012-09-12 | 米德列斯公司 | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
EP2380909A1 (en) | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
-
1996
- 1996-05-24 WO PCT/IB1996/000696 patent/WO1996037610A2/en active Application Filing
- 1996-05-24 AU AU62386/96A patent/AU6238696A/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
CHOU, Y.-H. AND HAYMAN, M.J.: "Characterization of a member of the immunoglobulin gene superfamily that possibly represents an additional class of growth factor receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 88, June 1991 (1991-06-01), pages 4897 - 4901, XP000605384 * |
LEE, S.-T. ET AL.: "A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes", ONCOGENE, vol. 8, 1993, pages 3403 - 3410, XP002016719 * |
MOSSIE, K. ET AL.: "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family", ONCOGENE, vol. 11, no. 10, 1995, pages 2179 - 2184, XP000605662 * |
PARK, S.-K. ET AL.: "Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG", THE JOURNAL OF BIOCHEMISTRY, vol. 119, February 1996 (1996-02-01), pages 235 - 239, XP000605383 * |
TAN, J.C. ET AL.: "The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase", SCIENCE, vol. 247, 12 January 1990 (1990-01-12), pages 209 - 212, XP000608226 * |
ULLRICH, A. AND SCHLESINGER, J.: "Signal transduction by receptors with tyrosine kinase activity", CELL, vol. 61, April 1990 (1990-04-01), pages 203 - 212, XP000471628 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996037610A2 (en) | 1996-11-28 |
AU6238696A (en) | 1996-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2239692A1 (en) | Diagnosis and treatment of aur-1 and/or aur-2 related disorders | |
WO1999037788A3 (en) | Diagnosis and treatment of aur1 and/or aur2 related disorders | |
Omri et al. | CD4 expression in neurons of the central nervous system | |
EP1361229A3 (en) | Use of Tyrosine Kinase (PYK2) to produce antibodies | |
WO1998031799A3 (en) | Polynucleotides and polypeptides encoding receptors | |
EP0771873A3 (en) | Neuronal cell-specific receptor protein | |
CA2158750A1 (en) | Monoclonal antibodies to casein kinase i polypeptides | |
WO1999024463A3 (en) | Signal peptide-containing proteins | |
CA2129969A1 (en) | DNA Encoding 5-HT4 Serotonin Receptors and Uses Thereof | |
CA2250075A1 (en) | Methods for diagnosing and treating alzheimer's disease | |
CA2145182A1 (en) | Dna encoding human alpha 1 adrenergic receptors and uses thereof | |
Lorigados et al. | Two‐site enzyme immunoassay for βNGF applied to human patient sera | |
WO1999007738A3 (en) | Human orphan receptor ntr-1 | |
WO1998026054A3 (en) | Pyk2 related products and methods | |
EP0789076A3 (en) | G protein coupled receptor proteins, their production and use | |
WO2002086076A3 (en) | Polynucleotides and polypeptides associated with the nf-kb pathway | |
WO1996037610A3 (en) | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders | |
MX9606584A (en) | Mass-sensitive biosensors. | |
WO1998049317A3 (en) | Diagnosis and treatment of phosphatase- 0r kinase-related disorders | |
WO2001040291A3 (en) | Proteins and nucleic acids encoding the same | |
DE69626860D1 (en) | ELISA TEST SYSTEM FOR DETERMINING SUBSTANCES INHIBITING THE BOND BETWEEN IG E AND ITS RECEPTOR | |
WO2000018916A3 (en) | Human genes and gene expression products | |
AU4654097A (en) | Rdgb-proteins | |
WO1999033967A3 (en) | Novel nucleic acid and polypeptide with homology to the tnf-receptors | |
WO2005003299A3 (en) | Polynucleotides encoding novel guanylate binding proteins (gbp's) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |